Details for New Drug Application (NDA): 210716
✉ Email this page to a colleague
The generic ingredient in TADALAFIL is tadalafil. There are twenty-five drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the tadalafil profile page.
Summary for 210716
| Tradename: | TADALAFIL |
| Applicant: | Chartwell Rx |
| Ingredient: | tadalafil |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 210716
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 2.5MG | ||||
| Approval Date: | Dec 29, 2020 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 5MG | ||||
| Approval Date: | Dec 29, 2020 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 10MG | ||||
| Approval Date: | Dec 29, 2020 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
